Overview

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

Eligibility

Inclusion Criteria:

• Have an increased waist-to-height ratio of ≥0.5
• Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia)
• Have at least one unsuccessful attempt to reduce body weight based on diet and exercise
• Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds

Exclusion Criteria:

• Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
• Do not have a stable body weight within 90 days before screening
• Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold)
• Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening
• Have a prior or planned surgical treatment or procedure for obesity
• Have hypertension or history of hypertension
• Have dyslipidemia or history of dyslipidemia